Skip to Main content Skip to Navigation
Journal articles

What are the therapeutic alternatives to dextropropoxyphene in France? A prescribers' survey.

Abstract : About a year after dextropropoxyphene (DXP) withdrawal from the French market, we conducted a survey among members of the French Society of Anesthesia & Intensive Care Medicine (Sfar) and of the French Society of the Study and Treatment of Pain (SFETD) to identify the indications for which this WHO level II analgesic had been prescribed, the prescriber's feedback following withdrawal, and the substitutive analgesics prescribed. DXP had been prescribed by more than 75% of the 430 anaesthesiologists and 230 pain specialists interviewed, mainly for acute and chronic non-cancer pain of moderate intensity. While two thirds of pain specialists were not satisfied with DXP withdrawal, this decision did not affect the majority of anaesthesiologists. In both groups, the main substitutive analgesic was tramadol combined with acetaminophen, while only 24% of prescribers considered acetaminophen alone as a substitute.
Document type :
Journal articles
Complete list of metadata

Cited literature [1 references]  Display  Hide  Download
Contributor : Laurent Jonchère Connect in order to contact the contributor
Submitted on : Monday, December 11, 2017 - 10:36:48 AM
Last modification on : Saturday, September 24, 2022 - 2:36:04 PM
Long-term archiving on: : Monday, March 12, 2018 - 12:18:07 PM


What are the therapeutic alter...
Files produced by the author(s)



F Aubrun, E Chrétien, L Letrilliart, M Ginoux, M Belhassen, et al.. What are the therapeutic alternatives to dextropropoxyphene in France? A prescribers' survey.. Anaesthesia Critical Care & Pain Medicine, Elsevier Masson, 2017, 36 (1), pp.15-19. ⟨10.1016/j.accpm.2016.01.007⟩. ⟨hal-01558315⟩



Record views


Files downloads